Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Jul;22(1):100–103.

Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.

R N Ratnaike, G J Schapel, G Purdie, R H Rischbieth, S Hoffmann
PMCID: PMC1401093  PMID: 3091053

Abstract

Erythrocyte (ENH3) and plasma (PNH3) ammonia levels, liver function tests and plasma valproate concentration were measured in 81 epileptic patients, comprising three therapeutic groups: Group 1 (23 patients) received sodium valproate (VPA) monotherapy, group 2 (33 patients) received sodium valproate combined with phenytoin, carbamazepine, phenobarbitone and/or primidone and group 3 (25 patients) received one or more of these anti-epileptic drugs without sodium valproate. The mean ENH3 and PNH3 of patients in group 1 (41.1 +/- 30.7 mumol l-1 and 37.1 +/- 31.8 mumol l-1, respectively) and group 2 (44.5 +/- 21.3 and 37.6 +/- 21.4 mumol l-1, respectively) were significantly (P less than 0.01) higher than those in group 3 (28.7 +/- 10.6 and 21.5 +/- 7.8 mumol l-1, respectively) and the reference range (30.1 +/- 7.9 and 20.8 +/- 5.7 mumol l-1, respectively). Hyperammonaemia was more prevalent amongst patients in group 2, for both ENH3 (45.5%) and PNH3 (54.6%), than amongst patients in group 1 (30.4% and 52.2%, respectively) and group 3 (8% and 8%, respectively). There was a significant (P less than 0.05) positive correlation between plasma VPA and total bilirubin concentrations. Chronic VPA therapy was also associated with an increase in bilirubin concentrations measured on average four months apart.

Full text

PDF
100

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buttery J. E., Ratnaike R. N., Chamberlain B. R. The measurement of erythrocyte ammonia using the Hyland Ammonia kit. J Clin Chem Clin Biochem. 1982 Jun;20(6):447–450. doi: 10.1515/cclm.1982.20.6.447. [DOI] [PubMed] [Google Scholar]
  2. Coude F. X., Grimber G., Parvy P., Rabier D., Petit F. Inhibition of ureagenesis by valproate in rat hepatocytes. Role of N-acetylglutamate and acetyl-CoA. Biochem J. 1983 Oct 15;216(1):233–236. doi: 10.1042/bj2160233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coulter D. L., Allen R. J. Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy. Lancet. 1980 Jun 14;1(8181):1310–1311. doi: 10.1016/s0140-6736(80)91773-0. [DOI] [PubMed] [Google Scholar]
  4. Kesterson J. W., Granneman G. R., Machinist J. M. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology. 1984 Nov-Dec;4(6):1143–1152. doi: 10.1002/hep.1840040609. [DOI] [PubMed] [Google Scholar]
  5. Kuta C. C., Maickel R. P., Borowitz J. L. Modification of drug action by hyperammonemia. J Pharmacol Exp Ther. 1984 Apr;229(1):85–90. [PubMed] [Google Scholar]
  6. Leary P. M. Liver function in children receiving treatment with the anticonvulsant sodium valproate. S Afr Med J. 1982 May 22;61(21):783–784. [PubMed] [Google Scholar]
  7. Marescaux C., Warter J. M., Micheletti G., Rumbach L., Coquillat G., Kurtz D. Stuporous episodes during treatment with sodium valproate: report of seven cases. Epilepsia. 1982 Jun;23(3):297–305. doi: 10.1111/j.1528-1157.1982.tb06195.x. [DOI] [PubMed] [Google Scholar]
  8. Murphy J. V., Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol. 1982 Sep;39(9):591–592. doi: 10.1001/archneur.1982.00510210061016. [DOI] [PubMed] [Google Scholar]
  9. Ratnaike R. N., Buttery J. E., Malden L. T., Chamberlain B. R., O'Halloran M. Erythrocyte ammonia in liver disease. Scand J Gastroenterol. 1983 Jan;18(1):103–106. doi: 10.3109/00365528309181567. [DOI] [PubMed] [Google Scholar]
  10. Ware S., Millward-Sadler G. H. Acute liver disease associated with sodium valproate. Lancet. 1980 Nov 22;2(8204):1110–1113. doi: 10.1016/s0140-6736(80)92543-x. [DOI] [PubMed] [Google Scholar]
  11. Warter J. M., Imler M., Marescaux C., Chabrier G., Rumbach L., Micheletti G., Krieger J. Sodium valproate-induced hyperammonemia in the rat: role of the kidney. Eur J Pharmacol. 1983 Feb 18;87(2-3):177–182. doi: 10.1016/0014-2999(83)90327-8. [DOI] [PubMed] [Google Scholar]
  12. Warter J. M., Marescaux C., Brandt C., Rumbach L., Micheletti G., Chabrier G., Imler M., Kurtz D. Sodium valproate associated with phenobarbital: effects on ammonia metabolism in humans. Epilepsia. 1983 Oct;24(5):628–633. doi: 10.1111/j.1528-1157.1983.tb03428.x. [DOI] [PubMed] [Google Scholar]
  13. Willmore L. J., Wilder B. J., Bruni J., Villarreal H. J. Effect of valproic acid on hepatic function. Neurology. 1978 Sep;28(9 Pt 1):961–964. doi: 10.1212/wnl.28.9.961. [DOI] [PubMed] [Google Scholar]
  14. Young R. S., Bergman I., Gang D. L., Richardson E. P., Jr Fatal Reye-like syndrome associated with valproic acid. Ann Neurol. 1980 Apr;7(4):389–389. doi: 10.1002/ana.410070423. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES